acute myocardial infarction

CHILL-MI: Hypothermia fails to show benefit in patients with acute ST- elevation IAM.

Hypothermia improves myocardial ischemia in animals but studies in humans failed to demonstrate benefit to that extent.We admitted 120 patients experiencing anterior-posterior STEMI with up to 6 hours after onset, randomized to conventional invasive therapy versus conventional invasive therapy associated with hypothermia. The primary endpoint was infarct size by MRI at 4 days.There was no<a href="https://solaci.org/en/2015/06/24/chill-mi-hypothermia-fails-to-show-benefit-in-patients-with-acute-st-elevation-iam/" title="Read more" >...</a>

PRAMI: Treating other lesions in addition to the culprit of an acute infarction reduces events.

In the context of an ST-segment elevation myocardial infarction, primary angioplasty to treat the culprit lesion improves the prognosis. The role of angioplasty in unrelated arteries is not well established. Between 2008 and 2013, 465 patients with myocardial infarction underwent primary angioplasty and were randomized to preventive (234 patients) vs non-preventive angioplasty (231 patients). The<a href="https://solaci.org/en/2015/06/24/prami-treating-other-lesions-in-addition-to-the-culprit-of-an-acute-infarction-reduces-events/" title="Read more" >...</a>

ACCOAST: Pretreatment with prasugrel showed no benefits and increased bleeding in patients with non-ST segment myocardial infarction.

This study evaluated the administration of prasugrel at the time of diagnosis of non-ST segment acute coronary syndrome vs administration at the time of the coronary angiography without indication of angioplasty. 4033 enrolled patients with non-ST segment acute coronary syndrome and positive troponin levels were randomized and who would undergo the angiography between 2 and<a href="https://solaci.org/en/2015/06/24/accoast-pretreatment-with-prasugrel-showed-no-benefits-and-increased-bleeding-in-patients-with-non-st-segment-myocardial-infarction/" title="Read more" >...</a>

EXAMINE: The alogliptin is safe for treating type 2 diabetes in patients with a recent history of acute coronary syndrome.

Type 2 diabetes is associated both microvascular and macrovascular disease. Adequate glycemic control can reduce the risk of many microvascular complications but have not shown the same effect on macrovascular complications. This study evaluates the results of alogliptin compared with placebo in patients with type 2 diabetes who had a recent acute coronary syndrome. The<a href="https://solaci.org/en/2015/06/24/examine-the-alogliptin-is-safe-for-treating-type-2-diabetes-in-patients-with-a-recent-history-of-acute-coronary-syndrome/" title="Read more" >...</a>

Reduced risk of acute, late and very late thrombosis with new generations of DES versus BMS in the acute myocardial context

Original title:&nbsp;Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR.&nbsp;Reference:&nbsp;Sarno G et al. J Am Coll Cardiol. 2014;Epub ahead of print. This study evaluated 34147 consecutive patients suffering acute myocardial infarction with ST-segment elevation included in the SCAAR registry (Swedish Coronary Angiography and Angioplasty Registry) undergoing primary<a href="https://solaci.org/en/2014/07/11/reduced-risk-of-acute-late-and-very-late-thrombosis-with-new-generations-of-des-versus-bms-in-the-acute-myocardial-context/" title="Read more" >...</a>

The radial access is a viable alternative in infarction complicated with cardiogenic shock

Original title:&nbsp;Arterial access site utilization in cardiogenic shock in the United Kingdom: Is radial access feasible?&nbsp;Reference:&nbsp;Mamas A. Mamas, et al. Am Heart J 2014;167:900-08 Cardiogenic shock in the context of acute myocardial infarction is associated with high mortality, and represents approximately 10% of major bleeding complications. Radial Access reduces mortality mainly by reducing bleeding; however,<a href="https://solaci.org/en/2014/06/05/the-radial-access-is-a-viable-alternative-in-infarction-complicated-with-cardiogenic-shock/" title="Read more" >...</a>

Severe coronary calcification is a predictor of coronary events in acute coronary syndromes

Original title:&nbsp;Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. Pooled Analysis From the HORIZONS and ACUITY Trials.&nbsp;Reference:&nbsp;Philippe G&eacute;n&eacute;reux, et al. J Am Coll Cardiol 2014;63:1845-54 Calcification of the arteries has always been a challenge and a generator of problems during coronary angioplasty, but its impact on acute coronary syndromes has not<a href="https://solaci.org/en/2014/05/21/severe-coronary-calcification-is-a-predictor-of-coronary-events-in-acute-coronary-syndromes/" title="Read more" >...</a>

Bivalirudin, effective in the pre-hospitalization phase of infarction

Original title:&nbsp;Bivalirudin Started during Emergency Transport for Primary PCI.&nbsp;Reference:&nbsp;Philippe G. Steg, et;al. NEJM 2013; Octubre 30:1-11 Primary PCI is the preferred treatment for AMI within the first 12 hours of symptom onset and outcomes have been improving with the incorporation of new strategies and technology. This study randomized 2218 STEMI patients started with bivalirudin during<a href="https://solaci.org/en/2013/11/05/bivalirudin-effective-in-the-pre-hospitalization-phase-of-infarction/" title="Read more" >...</a>

Ticagrelor reduces in-stent thrombosis in patients with acute coronary syndromes

Original title:&nbsp;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: An analysis from the prospective randomized PLATO trial.&nbsp;Reference:&nbsp;Steg PG et al. Circulation. 2013; Epub ahead of print The PLATO study randomized 18624 patients with acute coronary syndrome to receive ticagrelor &nbsp; (180 mg loading dose followed by 90 mg twice daily )<a href="https://solaci.org/en/2013/09/12/ticagrelor-reduces-in-stent-thrombosis-in-patients-with-acute-coronary-syndromes/" title="Read more" >...</a>

Rivaroxaban reduces in-stent thrombosis in patients with acute coronary syndromes

Original title:&nbsp;Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51.&nbsp;Reference:&nbsp;C. Michael Gibson et al. J Am Coll Cardiol 2013;62:286&ndash;90. There are few contemporary studies that investigated oral anticoagulation utility in patients with acute coronary syndromes and coronary angioplasty. Rivaroxaban is an oral anticoagulant that directly and<a href="https://solaci.org/en/2013/08/23/rivaroxaban-reduces-in-stent-thrombosis-in-patients-with-acute-coronary-syndromes/" title="Read more" >...</a>

Top